PROCLAIMSM

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM^SM registry
M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman, N. Gregory, D. F. McDermott

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 84; DOI: 10.1186/s40425-019-0567-3
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM^SM registry
Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 102; DOI: 10.1186/s40425-017-0307-5

Main menu